Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01441869 · ClinicalTrials.gov registry record · Phase 1
Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc
A Phase 1 study of Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT01441869: Completed Phase 1 study of Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin, sponsored by AstraZeneca.
NCT01441869 is a Phase 1 study of Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin that has completed, run by AstraZeneca. The registered enrollment target is 28 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01441869, a Phase 1 study of Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
Study in healthy subjects to measure amount of drug in blood after dosing with different saxagliptin / metformin products.
Conditions Studied
Interventions
- DRUG Onglyza (saxagliptin)
- DRUG Diabex
- DRUG 5-mg saxagliptin/1000 mg metformin
- DRUG 5-mg saxagliptin/500 mg metformin
Study Locations (1)
Kansas
- Research Site - Overland Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2011-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
What the finished NCT01441869 record still lists
NCT01441869 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin appearing as the primary indexed condition, and to 4 interventions - of which Onglyza (saxagliptin) is the first listed.
NCT01441869 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT01441869 about?
NCT01441869 is a clinical study titled "Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc". Study in healthy subjects to measure amount of drug in blood after dosing with different saxagliptin / metformin products.
What is the current status of trial NCT01441869?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2011-10. Estimated completion is 2011-12.
What conditions does trial NCT01441869 study?
This clinical trial studies the following conditions: Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin.
What interventions are being tested in trial NCT01441869?
The interventions under investigation include: Onglyza (saxagliptin) (DRUG), Diabex (DRUG), 5-mg saxagliptin/1000 mg metformin (DRUG), 5-mg saxagliptin/500 mg metformin (DRUG).
Who is sponsoring clinical trial NCT01441869?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01441869 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01441869's enrollment target sits among peer trials
28 1447th of 2000 higher than 538 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia